The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II, multicenter, placebo-controlled trial of apatinib in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after two previous treatment regimens.
Li Zhang
Consultant or Advisory Role - AstraZeneca; Boehringer Ingelheim; Lilly; Novartis
Honoraria - AstraZeneca; Aventis; Novartis; Roche
Research Funding - Aventis; Boehringer Ingelheim; GlaxoSmithKline; Novartis
Meiqi SHI
No relevant relationships to disclose
Cheng Huang
No relevant relationships to disclose
Xiaoqing Liu
No relevant relationships to disclose
Jian ping Xiong
No relevant relationships to disclose
Gongyan Chen
No relevant relationships to disclose
Wei Liu
No relevant relationships to disclose
Wenchao Liu
No relevant relationships to disclose
Yiping Zhang
No relevant relationships to disclose
Kai LI
No relevant relationships to disclose
Hao Yu
No relevant relationships to disclose
Haoyuan Jiang
Employment or Leadership Position - Ph.D., M.D., Medical Director